Edition:
United Kingdom

People: Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

1.75USD
9:00pm BST
Change (% chg)

$-0.05 (-2.78%)
Prev Close
$1.80
Open
$1.77
Day's High
$1.77
Day's Low
$1.71
Volume
32,700
Avg. Vol
69,835
52-wk High
$14.52
52-wk Low
$1.38

Rawcliffe, Adrian 

Mr. Adrian Rawcliffe is appointed as Chief Executive Officer, Director of the company., effective September 1, 2019. He leads our financial strategy, management and operations functions including compliance and risk management. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK's North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK's Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK's venture-capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --